← 홈

폐암 (NSCLC)

19개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 19개
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
ADCCBiologicstaleNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 79상태 DISCONTINUED
ADCBiologicstaleNovartis PharmaceuticalsPhase 2

Ribociclib (Ribociclib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · Breast Cancer

#BreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 66.7%임상시험 66상태 RECRUITING
AntibodystaleAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4
효능 ORR 77.8%임상시험 60상태 RECRUITING
ADCBiologicCullinan Therapeutics Inc.Deruxtecan-Dlnk Quantificat…Phase 1

Dato-DXd (Datopotamab deruxtecan-dlnk, Datopotamab deruxtecan-dlnk (Dato-DXd))

Advanced Solid Tumor; NSCLC · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 79%임상시험 39상태 RECRUITING
ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 3

Divarasib (Divarasib)

Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer · Solid Tumors

#SolidTumors#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
ADCBiologicstaleAmgenPhase 2

YL201 (YL201)

Small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 12상태 RECRUITING
AntibodystaleJeffrey ClarkePhase 1

AMG 479, Everolimus, Panitumumab (AMG 479, Everolimus, Panitumumab)

Advanced Solid Tumors, Non-small Cell Lung Cancer · Advanced Solid Tumors, Non-small Cell Lu

#AdvancedSolidTumorsNon-smallCell#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 2

CEA CAR-T cells (CEA CAR-T cells)

Solid Tumor; Lung Cancer · CEA

#CEA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleFamewave Ltd.Phase 2

nivolumab (Opdivo, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleFamewave Ltd.Phase 2

nivolumab (Opdivo, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
ADCBiologicstaleShanghai Henlius BiotechPhase 1

HLX42 (HLX42)

Solid Tumor and NSCLC · Solid Tumor and NSCLC

#SolidTumorandNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleMacroGenicsPhase 1

MGC028 (MGC028)

Advanced Solid Tumors; NSCLC Adenocarcinoma · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#항체#면역항체+3
효능 ORR 100%임상시험 1상태 RECRUITING